



Press release

Cantargia AB  
556791-6019  
2016-02-03

## Cantargia patent granted in Australia

**Cantargia AB ("Cantargia") has obtained a granted patent in Australia concerning IL1RAP as a target molecule for antibody based therapy and diagnostic methods of leukemia.**

Based on this grant, Cantargia's method for treatment of leukemia has protection within Europe, South Africa and Australia. The corresponding application is currently under review by authorities in e.g. USA, Japan and China.

**For further information, please contact**

Göran Forsberg, CEO  
Telephone: +46 (0)46-275 62 60  
E-mail: [goran.forsberg@cantargia.com](mailto:goran.forsberg@cantargia.com)

---

*Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing an antibody-based cancer treatment, which aims to attack cancer cells and decrease the tumour inflammation. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor associated protein "IL1RAP", in cancer stem cells in patients with leukemia that is not found in normal stem cells in the bone marrow. In preclinical studies (in vitro and in vivo) the antibody, targeted against IL1RAP, has been shown to have two potential mechanisms of action, which are complementary. The company has selected a product candidate for future studies in humans and development activities have been focused on non-small cell lung cancer and pancreatic cancer.*

*Cantargia is listed on NASDAQ First North Stockholm (ticker: CANTA). Sedermera Fondkommission is the company's Certified Adviser. More information about Cantargia is available at <http://www.cantargia.com>.*